About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human anti-thymocyte immunoglobulin (hIgG) for delaying the onset and progression of autoimmune type 1 diabetes (T1D), today announced that it will present at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) being held September 15 – 19, 2025 at the VIECON - Vienna Congress & Convention Center in Vienna, Austria. The Company will have four oral presentations, as well as an INNODIA-hosted symposium at EASD.

Information on all presentations is below:

INNODIA EASD Symposium | Life-Changing T1D Therapies Symposium

Working to Change the Lives of People Impacted by Type 1 Diabetes Through Unique Disease-Modifying Therapy
Presenter: Alexandra Kropotova, MD, MBA, EVP and Chief Medical Officer
Presentation Date & Time: Monday, September 15, 2025 | 16:40 – 20:00 CEST
Location: Lima Hall

EASD Presentations:

Immunomodulation Without Sustained Lymphodepletion: SAB-142, a Fully Human Anti-Thymocyte Globulin
Session: Behind the Screens: Adventures in T1D Clinical Trials | Presentation 19
Presenter: Alexandra Kropotova, MD, MBA, EVP and Chief Medical Officer
Presentation Date & Time: Tuesday, September 16, 2025 | 10:00 – 11:30 CEST
Location: Mumbai Hall

Mechanism of Action of a Fully Human Anti-Thymocyte Globulin, SAB-142, for the Treatment of Type 1 Diabetes
Session: OP 28 “Guardians of the Islet Galaxy: Protect and Replace” | Presentation 163
Presenter: Christoph Bausch, PhD, EVP and Chief Operating Officer
Presentation Date & Time: Thursday, September 18, 2025 | 10:45 – 12:15 CEST
Location: Sofia Hall

Novel Pharmacokinetic Assay for Measuring SAB-142, a Fully Human Anti-Thymocyte Globulin
Session: Clinical Tales from the T1D Trenches | Short Oral Discussion - Event F | Presentation 391
Presenter:   Eric Sandhurst, PhD, Director of Program Management
Presentation Date & Time: Thursday, September 18, 2025 | 14:00 – 15:00 CEST
Location: Station 03, Hall C

Specimen Quality for Multicenter Clinical Trials: Comparing Novel Blood Preservation Methods to Cryopreserved PBMC
Session: Clinical Tales from the T1D Trenches | Short Oral Discussion - Event F | Presentation 392
Presenter:   Eric Sandhurst, PhD, Director of Program Management
Presentation Date & Time:   Thursday, September 18, 2025 | 14:00 – 15:00 CEST
Location: Station 03, Hall C

About EASD Annual Meeting

The EASD Annual Meeting is the largest diabetes conference in the world, attracting thousands of delegates. The program showcases the latest results from basic and clinical research.

For more information, visit https://www.easd.org/annual-meeting/easd-2025/.

About INNODIA

INNODIA is an international non-profit organization that stemmed from a European-based public-private partnership co-funded by the European Commission’s Innovative Medicines Initiative (IMI-JU Joint Undertaking), The Hemsley Charitable Trust, Breakthrough T1D, and EFPIA partners. Thanks to this unique private-public interaction, INNODIA has become the largest European Network dedicated to prevent and cure type 1 diabetes and today it is a legal entity that represents the interface between those who want to develop new therapies and those who have the tools and experience to do so.

For more information, visit https://www.innodia.eu/.

About SAB BIO

SAB BIO is a clinical-stage biopharmaceutical company focused on developing human, multi-specific, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™, the only transgenic animal with a human artificial chromosome, SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors.

CONTACTS

Investor Relations:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

Media Inquiries:
SAB BIO
Sheila Carlson
scarlson@sab.bio


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.